Skip to main content
. 2022 Jul 8;9:921675. doi: 10.3389/fmed.2022.921675

TABLE 1.

Demographic and clinical variables relative to the studied population of subjects.

Controls No. 20 ERA T0 No. 19 ERA T1 No. 19 Significance
Sex male n (%) 1 (5%) 9 (45%) a
Age (years) median (IQR) 53.5 (40.8–56.0) 61.0 (46.5–66.5)
ACPA median (IQR) 0 (0–0) 320.0 (206.5–566.0) 92.0 (30.7–268.5) a,b
RF median (IQR) 0 (0–0) 86.0 (23.5–237.5) 20.5 (0–59.2) a,b
ESR median (IQR) 12.0 (8.0–19.2) 35.0 (21.5–52.5) 13.5 (6.0–20.0) a,b
CRP median (IQR) 0.055 (0–0.2) 1.0 (0.41–1.45) 0.2 (0.07–0.37) a,b
CDAI 21.5 (17.0–31.7) 3.5 (2.25–16) b
SDAI 23.5 (18.0–37.5) 3.5 (2.25–17.875) b
DAS28 5.5 (4.4–6.3) 2.3 (1.9–3.8) b
CD4plus% median (IQR) 40 (31.5–45.2) 42.0 (38.0–45.8) 38.7 (34.2–42.6)
Treg% median (IQR) 1.4 (1.1–1.8) 1.0 (0.8–1.3) 1.1 (1.0–1.8) a,b
Th17% median (IQR) 0.85 (0.77–1.22) 1.8 (1.3–2.7) 1.5 (1.0–2.2) a,b
IL9 median (IQR) 2.8 (0.7–3.2) 2.6 (1.9–11.9) 2.6 (1.0–5.4)
TGFb median (IQR) 2513.4 (1782.7–3790.6) 1919.7 (1108.6–4185.5) 1903.4 (566.0–4103.7)
TNF-alpha 3.3 (0–8.3) 0 (0–1.3) b
IL6 35.1 (16.1–49.8) 13.6 (8.5–21.6) b

Statistical significance at alpha levels 0.05. a: Controls vs. ERA T0, b: ERA T0 vs. ERA T1.